Gland Pharma Ltd appoints Xiao Le as Chief Investment Officer of its wholly owned subsidiary, effective November 9, 2026
- Xiao Le will explore investment opportunities and strengthen M&A capabilities across the US, China, Singapore and other markets.
- He will report to the CEO of Gland Pharma International Pte. Ltd.
- He brings more than 15 years of investment and asset-management experience across healthcare.
